Scarica l'app Stockscreener
22.60
5.44%
-1.30
Precedente Chiudi:
$23.90
Aprire:
$23.57
Volume 24 ore:
1.63M
Relative Volume:
0.94
Capitalizzazione di mercato:
$1.69B
Reddito:
$254.91M
Utile/perdita netta:
$-103.48M
Rapporto P/E:
-16.10
EPS:
-1.4036
Flusso di cassa netto:
$-148.35M
1 W Prestazione:
+0.00%
1M Prestazione:
-22.68%
6M Prestazione:
+98.07%
1 anno Prestazione:
+2.91%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$21.73
$24.26
Portata 52W:
$10.95
$33.78
Schrodinger Inc Stock (SDGR) Company Profile
Nome
Schrodinger Inc
Settore
Industria
Telefono
503-299-1150
Indirizzo
1540 BROADWAY, NEW YORK, NY
Compare SDGR vs VEEV, BTSG, TEM, HNGE, HQY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
22.60 | 1.69B | 254.91M | -103.48M | -148.35M | -1.4036 |
VEEV
Veeva Systems Inc
|
322.55 | 52.22B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
60.86 | 12.04B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
63.81 | 11.59B | 1.36B | -302.91M | -219.93M | -1.7182 |
HNGE
Hinge Health Inc
|
109.93 | 8.87B | 646.34M | -512.40M | 202.76M | -6.6871 |
HQY
Healthequity Inc
|
100.97 | 8.35B | 1.34B | 230.70M | 440.96M | 2.6695 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-08-14 | Ripresa | UBS | Neutral |
| 2025-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-09-30 | Iniziato | Goldman | Neutral |
| 2025-08-15 | Downgrade | Citigroup | Buy → Neutral |
| 2025-08-14 | Iniziato | Barclays | Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-07-02 | Iniziato | Leerink Partners | Outperform |
| 2023-12-05 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2023-05-05 | Ripresa | Piper Sandler | Overweight |
| 2022-12-19 | Iniziato | Goldman | Neutral |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2021-11-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-10-13 | Iniziato | Berenberg | Buy |
| 2021-09-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-05-25 | Iniziato | Craig Hallum | Buy |
| 2020-11-23 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-10-12 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-02 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-02 | Iniziato | Jefferies | Hold |
| 2020-03-02 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Schrodinger Inc Borsa (SDGR) Ultime notizie
Schrödinger to Announce Third Quarter 2026 Financial Results on November 4 - Business Wire
Certara, Inc. (CERT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Up to 40% of lithium ions in battery fluid cluster. This could help guide battery design. - Stock Titan
Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains? - Zacks Investment Research
Global Drug Discovery AI Tools MarketStrategic Forecast 2026-2032 | Generative AI, Cloud Platforms, and Integrated R&D Workflows Create New Growth Opportunities - GlobeNewswire Inc.
Biosimulation Market Set for Strong Growth Through 2035, Fueled by AI-Driven Drug Discovery, Virtual Trials and Precision Medicine Demand - GlobeNewswire Inc.
Early Warning Disclosure Regarding Common Shares of Irruptive Metals Corp. - Yahoo Finance
Schrodinger president Karen Akinsanya sells $927,970 in company stock By Investing.com - Investing.com Nigeria
Schrodinger president Karen Akinsanya sells $927,970 in company stock By Investing.com - Investing.com South Africa
Schrodinger president Karen Akinsanya sells $927,970 in company stock - Investing.com India
Options at $4.34 become shares sold near $30 for Schrodinger (SDGR) insider - Stock Titan
Schrodinger Insider Sold Shares Worth $927,970, According to a Recent SEC Filing - Yahoo Finance
Schrodinger president Karen Akinsanya sells $927,970 in company stock - Investing.com
Schrodinger Inc. (SDGR) Pulls Back 4.03% to $29.02, Nearing Key SupportCharm Flow - dars.gov.et
Host Digital Inc. Announces Common Stock Offering - Yahoo Finance
Insider at Schrodinger (NASDAQ: SDGR) plans September 2026 stock sale - Stock Titan
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Schrödinger Stock Adds 26% and $472 Million of Market Value; Tectora’s Terms Stay Private - TechStock²
Understanding the Setup: (SDGR) and Scalable Risk - Stock Traders Daily
Schrödinger introduces Tectora Therapeutics - BioWorld News
Tectora Therapeutics inc. announced that it has received $55 million in funding from New Enterprise Associates, Inc., RA Capital Management, L.P., Schrödinger, Inc. - marketscreener.com
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs - BioSpace
SDGR Looks 19.2% Undervalued on GF Value™ - GuruFocus
Schrodinger Establishes Tectora Therapeutics With RA Capital, New Enterprise Associates - marketscreener.com
A new drug company raises $55 million for oral medicines - Stock Titan
Is Schrodinger Inc (SDGR) a Bargain After 3.1% Drop? GF Value Sa - GuruFocus
Schrodinger (SDGR) Slips 1.3% as Shares Hold Above Key $19.58 SupportPut Flow Alert - dars.gov.et
Schrodinger (SDGR) Slips 1.3% as Shares Hold Above Key $19.58 SupportUp Down Volume - vinanet.vn
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? - TradingView
“Schrodinger’s Strait:” Why Hormuz Now Exists in a State of Permanent Uncertainty - Yahoo Finance
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030 - PR Newswire
Schrödinger’s Strait - الحرة
Price-Driven Insight from (SDGR) for Rule-Based Strategy - Stock Traders Daily
Drug Discovery Platforms Market to Reach USD 16.5 Billion by 2036, Driven by AI-Powered Research and Rising Pharmaceutical R&D Investment - industrytoday.co.uk
Schrödinger to Present at Morgan Stanley Global Healthcare Conference 2026 - BioSpace
Schrödinger to Present at Morgan Stanley Global Healthcare Conference - Business Wire
Schrodinger Inc. (SDGR) Slips 1.81% to $20.04 as Stock Holds Above Key SupportInsider Selling Alerts - dars.gov.et
SDGR | Schrodinger, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Schrödinger: The Software Business Is Stronger Than It Looks (NASDAQ:SDGR) - Seeking Alpha
Tejara Capital Ltd Takes $4.55 Million Position in Schrodinger, Inc. $SDGR - MarketBeat
Schrödinger (SDGR) Q2 2026 Earnings Call Transcript - AOL.ca
Schrodinger (NASDAQ:SDGR) Trading 10.4% HigherWhat's Next? - MarketBeat
BMO Capital Maintains Schrodinger(SDGR.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Schrodinger Inc (SDGR) News, Articles, Events & Latest Updates - Stocktwits
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci - Zacks Investment Research
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci - Yahoo Finance
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci - The Globe and Mail
Schrödinger-BMS collaboration centers on Bunsen for trillion-scale computational drug discovery - drugdiscoverytrends.com
Schrodinger Inc. (SDGR) Slides 4.7% to $17.59 as Bearish Momentum BuildsCounter Trend Trade - Vinanet
SDGR Looks 29.7% Undervalued on GF Value™ - GuruFocus
Schrodinger Inc Azioni (SDGR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Schrodinger Inc Azioni (SDGR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Akinsanya Karen | See Remarks |
Sep 17 '26 |
Sale |
29.37 |
31,599 |
927,970 |
69,956 |
| KAREN OLUFUNMILYO AKINSANYA-AK | Officer |
Sep 17 '26 |
Proposed Sale |
23.93 |
31,599 |
756,164 |
0 |
| Jain Rachit | EVP & CFO |
Jul 16 '26 |
Sale |
15.60 |
875 |
13,647 |
50,877 |
| Jain Rachit | Officer |
Jul 16 '26 |
Proposed Sale |
15.60 |
875 |
13,647 |
0 |
| Aklian Mannix Vartan | Officer |
Jul 01 '26 |
Proposed Sale |
16.68 |
1,136 |
18,949 |
0 |
| Herman Jenny | Officer |
May 01 '26 |
Proposed Sale |
12.26 |
1,957 |
24,000 |
0 |
| Farid Ramy | President & CEO |
Apr 17 '26 |
Option Exercise |
3.07 |
117,527 |
360,808 |
405,351 |
| Farid Ramy | President & CEO |
Apr 17 '26 |
Sale |
12.21 |
43,000 |
524,944 |
330,824 |
| Farid Ramy | President & CEO |
Apr 16 '26 |
Option Exercise |
3.07 |
43,000 |
132,010 |
373,824 |
| Farid Ramy | President & CEO |
Apr 16 '26 |
Sale |
12.33 |
43,000 |
530,233 |
330,824 |
2.09%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):